202 related articles for article (PubMed ID: 20066473)
1. Metronomic treatment of malignant glioma xenografts with irinotecan (CPT-11) inhibits angiogenesis and tumor growth.
Takano S; Kamiyama H; Mashiko R; Osuka S; Ishikawa E; Matsumura A
J Neurooncol; 2010 Sep; 99(2):177-85. PubMed ID: 20066473
[TBL] [Abstract][Full Text] [Related]
2. Vascular endothelial growth factor expression is closely related to irinotecan-mediated inhibition of tumor growth and angiogenesis in neuroblastoma xenografts.
Kaneko S; Ishibashi M; Kaneko M
Cancer Sci; 2008 Jun; 99(6):1209-17. PubMed ID: 18384433
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of hypoxia inducible factor-1alpha (HIF-1alpha) decreases vascular endothelial growth factor (VEGF) secretion and tumor growth in malignant gliomas.
Jensen RL; Ragel BT; Whang K; Gillespie D
J Neurooncol; 2006 Jul; 78(3):233-47. PubMed ID: 16612574
[TBL] [Abstract][Full Text] [Related]
4. Anti-angiogenic effects of SN38 (active metabolite of irinotecan): inhibition of hypoxia-inducible factor 1 alpha (HIF-1alpha)/vascular endothelial growth factor (VEGF) expression of glioma and growth of endothelial cells.
Kamiyama H; Takano S; Tsuboi K; Matsumura A
J Cancer Res Clin Oncol; 2005 Apr; 131(4):205-13. PubMed ID: 15583935
[TBL] [Abstract][Full Text] [Related]
5. Potent and sustained inhibition of HIF-1α and downstream genes by a polyethyleneglycol-SN38 conjugate, EZN-2208, results in anti-angiogenic effects.
Sapra P; Kraft P; Pastorino F; Ribatti D; Dumble M; Mehlig M; Wang M; Ponzoni M; Greenberger LM; Horak ID
Angiogenesis; 2011 Sep; 14(3):245-53. PubMed ID: 21452059
[TBL] [Abstract][Full Text] [Related]
6. Knockdown of Nrf2 suppresses glioblastoma angiogenesis by inhibiting hypoxia-induced activation of HIF-1α.
Ji X; Wang H; Zhu J; Zhu L; Pan H; Li W; Zhou Y; Cong Z; Yan F; Chen S
Int J Cancer; 2014 Aug; 135(3):574-84. PubMed ID: 24374745
[TBL] [Abstract][Full Text] [Related]
7. Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib.
Bocci G; Falcone A; Fioravanti A; Orlandi P; Di Paolo A; Fanelli G; Viacava P; Naccarato AG; Kerbel RS; Danesi R; Del Tacca M; Allegrini G
Br J Cancer; 2008 May; 98(10):1619-29. PubMed ID: 18443598
[TBL] [Abstract][Full Text] [Related]
8. Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice.
Allegrini G; Goulette FA; Darnowski JW; Calabresi P
Cancer Chemother Pharmacol; 2004 Mar; 53(3):261-6. PubMed ID: 14658007
[TBL] [Abstract][Full Text] [Related]
9. Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer.
Fioravanti A; Canu B; Alì G; Orlandi P; Allegrini G; Di Desidero T; Emmenegger U; Fontanini G; Danesi R; Del Tacca M; Falcone A; Bocci G
Eur J Pharmacol; 2009 Oct; 619(1-3):8-14. PubMed ID: 19695243
[TBL] [Abstract][Full Text] [Related]
10. The Ketogenic Diet Alters the Hypoxic Response and Affects Expression of Proteins Associated with Angiogenesis, Invasive Potential and Vascular Permeability in a Mouse Glioma Model.
Woolf EC; Curley KL; Liu Q; Turner GH; Charlton JA; Preul MC; Scheck AC
PLoS One; 2015; 10(6):e0130357. PubMed ID: 26083629
[TBL] [Abstract][Full Text] [Related]
11. Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition.
Rapisarda A; Hollingshead M; Uranchimeg B; Bonomi CA; Borgel SD; Carter JP; Gehrs B; Raffeld M; Kinders RJ; Parchment R; Anver MR; Shoemaker RH; Melillo G
Mol Cancer Ther; 2009 Jul; 8(7):1867-77. PubMed ID: 19584228
[TBL] [Abstract][Full Text] [Related]
12. Regression of glioma tumor growth in F98 and U87 rat glioma models by the Nitrone OKN-007.
Towner RA; Gillespie DL; Schwager A; Saunders DG; Smith N; Njoku CE; Krysiak RS; Larabee C; Iqbal H; Floyd RA; Bourne DW; Abdullah O; Hsu EW; Jensen RL
Neuro Oncol; 2013 Mar; 15(3):330-40. PubMed ID: 23328810
[TBL] [Abstract][Full Text] [Related]
13. RNA interference targeting hypoxia-inducible factor 1α via a novel multifunctional surfactant attenuates glioma growth in an intracranial mouse model.
Gillespie DL; Aguirre MT; Ravichandran S; Leishman LL; Berrondo C; Gamboa JT; Wang L; King R; Wang X; Tan M; Malamas A; Lu ZR; Jensen RL
J Neurosurg; 2015 Feb; 122(2):331-41. PubMed ID: 25423275
[TBL] [Abstract][Full Text] [Related]
14. Knockdown of Hypoxia-Inducible Factor 1α Improved the Efficacy of Low-Dose Metronomic Chemotherapy of Paclitaxel in Human Colon Cancer Xenografts.
Zhang M; Chen C; Su F; Huang Z; Li X; Li X
Technol Cancer Res Treat; 2017 Oct; 16(5):609-619. PubMed ID: 27573201
[TBL] [Abstract][Full Text] [Related]
15. Combined targeting of interleukin-6 and vascular endothelial growth factor potently inhibits glioma growth and invasiveness.
Saidi A; Hagedorn M; Allain N; Verpelli C; Sala C; Bello L; Bikfalvi A; Javerzat S
Int J Cancer; 2009 Sep; 125(5):1054-64. PubMed ID: 19431143
[TBL] [Abstract][Full Text] [Related]
16. Prolonged low-dose administration of the cyclooxygenase-2 inhibitor celecoxib enhances the antitumor activity of irinotecan against neuroblastoma xenografts.
Kaneko M; Kaneko S; Suzuki K
Cancer Sci; 2009 Nov; 100(11):2193-201. PubMed ID: 19673886
[TBL] [Abstract][Full Text] [Related]
17. Antitumor effects of 2-oxoglutarate through inhibition of angiogenesis in a murine tumor model.
Matsumoto K; Obara N; Ema M; Horie M; Naka A; Takahashi S; Imagawa S
Cancer Sci; 2009 Sep; 100(9):1639-47. PubMed ID: 19575748
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of anti-tumor activity by low-dose combination of the recombinant urokinase kringle domain and celecoxib in a glioma model.
Kim CK; Joe YA; Lee SK; Kim EK; O E; Kim HK; Oh BJ; Hong SH; Hong YK
Cancer Lett; 2010 Feb; 288(2):251-60. PubMed ID: 19664879
[TBL] [Abstract][Full Text] [Related]
19. Effects of convection-enhanced delivery of bevacizumab on survival of glioma-bearing animals.
Wang W; Sivakumar W; Torres S; Jhaveri N; Vaikari VP; Gong A; Howard A; Golden EB; Louie SG; Schönthal AH; Hofman FM; Chen TC
Neurosurg Focus; 2015 Mar; 38(3):E8. PubMed ID: 25727230
[TBL] [Abstract][Full Text] [Related]
20. Neural stem cell-mediated delivery of irinotecan-activating carboxylesterases to glioma: implications for clinical use.
Metz MZ; Gutova M; Lacey SF; Abramyants Y; Vo T; Gilchrist M; Tirughana R; Ghoda LY; Barish ME; Brown CE; Najbauer J; Potter PM; Portnow J; Synold TW; Aboody KS
Stem Cells Transl Med; 2013 Dec; 2(12):983-92. PubMed ID: 24167321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]